Imagen de Portada

Long-Term Results of Segmentectomy vs. Lobectomy for c-Stage IA Lung Cancer: A Real-Life Study with a Propensity Score Analysis Based on a National Cohort

Guardado en:
Publicado en:Journal of Clinical Medicine vol. 14, no. 7 (2025), p. 2267
Autor principal: Lopez, Iker
Otros Autores: Aguinagalde, Borja, Ferrer-Bonsoms, Juan A, Sánchez, Laura, Ascanio, Fernando, Sesma, Julio, Recuero, José Luis, Fernandez-Monge, Arantza, Lizarbe, Jon A, Embun, Raul
Publicado:
MDPI AG
Materias:
Clinical trials
Observational studies
Lung cancer
Ethics
Tumors
Thoracic surgery
Epidemiology
Values
Survival analysis
Lymphatic system
Acceso en línea:Citation/Abstract
Full Text + Graphics
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Resumen:Background/Objectives: The objective was to compare the results of segmentectomy and lobectomy in the treatment of c-stage IA lung cancer in terms of tumor recurrence and 5-year survival. Methods: An observational study was performed using 3533 patients included in the registry of the Spanish VATS Group (GEVATS) of the Spanish Society of Thoracic Surgery (SECT) between 2016 and 2018. A total of 1004 lobectomies and 83 segmentectomies in c-stage IA were selected. Two comparable groups were selected through 2:1 propensity score matching with patient-, tumor- and surgery-related variables, leaving 166 lobectomies and 83 segmentectomies. Tumor recurrence was analyzed by Fisher’s test and overall, cancer-specific, recurrence-free and disease-free survival by Kaplan-Meier and Log-rank tests. Results: Overall recurrence was 23.7% in both groups, with a predominance of locoregional recurrence in segmentectomy (16.2% vs. 11.2%) and distant recurrence in lobectomy (12.5% vs. 7.5%). There was no difference between the two groups in any of the survival types. Overall survival at 5 years was 73.5% (95% CI: 65.5–82.4%) in the lobectomy group vs. 73.1% (95% CI: 60.1–88.9%) in the segmentectomy group. Conclusions: Anatomic segmentectomy may be a valid option in the treatment of c-stage IA lung cancer since the recurrence and long-term survival outcomes compared to lobectomy are equivalent.
ISSN:2077-0383
DOI:10.3390/jcm14072267
Fuente:Health & Medical Collection